Skip to main content
. Author manuscript; available in PMC: 2021 Mar 28.
Published in final edited form as: Oncogene. 2020 Sep 28;39(45):6935–6949. doi: 10.1038/s41388-020-01479-6

Figure 5: Characterization of LNCaP variant under long-term ARSi-equivalent conditions (i.e. LN-95 cells).

Figure 5:

a) AR-FL and AR-V7 immunoblot of LNCaP vs. LN-95 variant and quantification via densitometry. b) Cell number after 5 days of in vitro growth of LN-95 in 10% FBS media, 10% FBS media containing 10 μM enzalutamide, or 10% CS-FBS media vs. LNCaP growth under the same conditions with asterisks denoting significant difference at p < 0.05. c) Growth rate of LN-95 in castrated (i.e. ARSi-equivalent) vs. LNCaP in intact (i.e. ADT-equivalent) mice. d) Abi resistance of LN-95 xenografts in vivo (n = 3 each). e) In vivo growth response of LN-95 growing in castrated (i.e. ARSi-equivalent) male NSG mice given daily oral dosing with 25 mg of enzalutamide/kg/d vs. vehicle controls (n = 5 each).